Pityriasis rosea-like adverse reaction: Review of the literature and experience of an Italian drug-surveillance center

Atzori, Laura; Pinna, Al; Ferreli, Caterina; Aste, Nicola

doi:10.5070/d380d8301d

Cited by 50 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5 Conversely, pityriasis rosea has been reported after vaccinations or drug use. 6,7 It appears remarkable that urticarial, pityriasis rosea-like rashes or chilblain-like changes have been frequently reported during or after COVID-19. [8][9][10] For two patients (nr.…”

mentioning

confidence: 99%

Cutaneous adverse reactions after m‐RNA COVID‐19 vaccine: early reports from Northeast Italy

Farinazzo

Ponis

Zelin

et al. 2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

as PR-like eruptions may have peripheral eosinophilia, interface dermatitis and eosinophils on histopathology, with no evidence of HHV-6 and HHV-7 systemic reactivation. 3 Our cases had overlapping features of both PR and PR-like eruptions.COVID-19 has been associated with cases of PR and PRlike eruptions following the acute infection. 6,7 Skin biopsies may demonstrate positivity for the SARS-CoV-2 virus spike protein on endothelial cells and lymphocytes suggesting a direct relationship between SARS-CoV-2 infection and PR. 7 SARS-CoV-2 may also trigger PR by reactivation of HHV-6 or HHV-7. 5 PR eruptions have developed following vaccination for influenza and H1N1 8-10 and may be secondary to reactivation of HHV-6 and HHV-7, which may be detected in skin biopsies via in situ hybridization and immunohistochemistry. 9 Another possible cause for PR in the setting of vaccination is a T-cell-mediated response triggered by molecular mimicry from a viral epitope. 8 Given worldwide vaccination efforts against COVID-19 with mRNA vaccines, it is important for doctors and patients to recognize possible adverse events including PR. Further study is required to confirm the causative link, including direct examination of tissue and serological studies for evidence of HHV-6 and HHV-7 reactivation.

show abstract

mentioning

confidence: 99%

Cutaneous adverse reactions after m‐RNA COVID‐19 vaccine: early reports from Northeast Italy

Farinazzo

Ponis

Zelin

et al. 2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…[32][33][34][35] Pityriasis rosea, a self-limiting exanthematous disease supposedly caused by reactivation of HHV-6/7, has been discussed to be associated with immune reactions following application of drugs and vaccinations. 36,37 Some groups even distinguish between pityriasis rosea-like eruptions, occurring after infections or in the context of medication or vaccination as a kind of drug eruption and "classic" pityriasis rosea arising sporadically and irrespectively of the aforementioned. 38 Recently, pityriasis rosea after both COVID-19 infection and COVID-19 vaccination have been published.…”

Section: Discussionmentioning

confidence: 99%

Cutaneous reactions following COVID‐19 vaccination assessed by dermatologists: a single‐institutional study in Germany

Wang

Mathes

Claussen

et al. 2023

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Summary Background and objectives Cutaneous reactions following COVID‐19 vaccination have been frequently described, whereas larger case series by dermatologists are lacking. This study assesses SARS‐CoV‐2 vaccination‐associated skin reactions, severity, treatment, course, eliciting vaccines, allergy test results and tolerance to revaccination. Patients and methods Single‐institutional, non‐interventional study of dermatologists assessing cutaneous manifestations in 83 patients in Germany. Results 93 reactions were presented. Manifestations clustered into immediate (n = 51, 54.8%) and delayed hypersensitivity reactions (n = 10, 10.8%), chronic inflammatory skin diseases (n = 13, 14.0%), reactivation of latent herpes virus infection (pityriasis rosea/herpes zoster; n = 9; 9.7%) and others (n = 10, 10.8%). Vaccination was associated with new (76.3%) – mostly hypersensitivity reactions – or exacerbation of known skin diseases (23.7%), in this case predominantly chronic inflammatory skin diseases. Reactions occurred primarily within the first week (72.8%) and after first vaccination (62.0%). Treatment was required in 83.9% and hospitalization in 19.4%. In 48.8% revaccination led to recurrence of the same reactions. Disease was ongoing at last consultation in 22.6%, primarily in chronic inflammatory skin diseases. Allergy tests were performed in 15 patients (18.1%) and resulted negative. Conclusions It can be assumed that vaccination may trigger immune activation‐related reactions especially in those patients predisposed to develop respective skin diseases.

show abstract

“…Pityriasis rosea-like drug eruptions have been reported with non-steroidal anti-inflammatory drugs and angiotensin converting enzyme inhibitors, among many other drugs. 8 In these cases, the mechanism underlying the eruption is unclear and resolution was achieved with drug withdrawal. Duration greater than 3 months and biopsy showing increased eosinophilic infiltrate can help distinguish a pityriasis rosea-like drug eruption from pityriasis rosea.…”

Section: Discussionmentioning

confidence: 99%

Dupilumab-induced pityriasis rosea

Zabel¹,

Hile²,

Shefler³

et al. 2023

JAAD Case Reports

View full text Add to dashboard Cite

Pityriasis rosea-like adverse reaction: Review of the literature and experience of an Italian drug-surveillance center

Cited by 50 publications

References 0 publications

Cutaneous adverse reactions after m‐RNA COVID‐19 vaccine: early reports from Northeast Italy

Cutaneous adverse reactions after m‐RNA COVID‐19 vaccine: early reports from Northeast Italy

Cutaneous reactions following COVID‐19 vaccination assessed by dermatologists: a single‐institutional study in Germany

Dupilumab-induced pityriasis rosea

Contact Info

Product

Resources

About